19
Participants
Start Date
November 18, 2021
Primary Completion Date
May 13, 2022
Study Completion Date
May 14, 2022
Ganaplacide
Treatment A/Period 1: 400 mg (4 x 100 mg tablets) at Hour 0 on Day 1 Treatment B/Period 2: 400 mg (4 x 100 mg tablets) at Hour 0, approximately 2 hours after itraconazole dosing, on Day 5.
Lumefantrine
Treatment A/Period 1: 480 mg (2 x 240 mg sachets) at Hour 0 on Day 1 Treatment B/Period 2: 480 mg (2 x 240 mg sachets) at Hour 0, approximately 2 hours after itraconazole dosing, on Day 5.
Itraconazole
200 mg (20 mL of 10 mg/mL oral solution) q.d. on Days 1 to 18
Novartis Investigative Site, Belfast
Lead Sponsor
Medicines for Malaria Venture
OTHER
Novartis Pharmaceuticals
INDUSTRY